If you would like to submit a blog post for consideration, please email email@example.com
Artificial intelligence has the capacity to revolutionise skin cancer medicine, with multiple programs in development that aid in the early detection of the disease. One such program is Doctor Hazel – a platform that could someday identify cancerous moles with a success rate of 90 percent, provided it attracts enough user submissions.
Still in its infancy, Doctor Hazel was demonstrated earlier this week by a team of engineers at TechCrunch’s Disrupt San Francisco 2017 hackathon. The artificial intelligence program currently identifies cancer at an 85 percent success rate; however, the team has launched a beta and is inviting users to submit their own photos to improve the platform’s performance.
This month’s research article is a scholarly review from the British Journal of Dermatology. The topic of the article is actinic keratosis (AK), which is such a common condition – and $1 billion is spent in the US each year treating it. Continue reading “Treating Actinic Keratosis In Primary Care”
In this skin cancer update video, Associate Professor Giuseppe Argenziano shares the results of a meta-analysis of nevus-associated melanoma. The study asked whether a nevus was a precursor lesion of melanoma.
It found that only a third of melanomas arise from a pre-existing nevus, and the majority of melanomas developed from nondysplastic nevi.
People who snack late at night could be at higher risk of skin cancer, according to a new study from the O’Donnell Brain Institute and UC Irvine.
A study in mice found that eating at abnormal times disrupted the skin’s biological clock, including the potency of an enzyme that protects against the sun’s harmful ultraviolet radiation in the daytime.
Vitamin B3 could potentially help prevent melanoma in people most at risk of developing the deadly skin cancer, according to a paper published in the Photodermatology, Photoimmunology & Photomedicine journal.
The paper’s author, Dr Gary Halliday, wrote that nicotinamide (or vitamin B3), was shown to reduce the incidence of non-melanoma skin cancer in high-risk individuals in a clinical trial called ONTRAC.
The Professor of Dermatology at the University of Sydney believes it would be worthwhile to further determine whether the vitamin can help prevent melanoma in high-risk patients such as outdoor workers, people with fair skin, and those aged over 40.
Dr Halliday said that vitamin B3 ought to be investigated as an inexpensive way of preventing the disease in people who are most susceptible to developing it, since nicotinamide has been proven to enhance DNA repair and reduce inflammation caused by UV radiation.
While such a clinical trial would be welcomed, it is important to await the results of a study before recommending vitamin B3 as a preventative measure for melanoma, which is the fourth most common cancer in Australia.
(10 August 2017) Vitamin B may help prevent melanoma. SBS.
You might be interested in:
- Professional Certificate of Skin Cancer Medicine | Enrol now
Dermoscopy | Biopsy techniques | Surgical treatments | Topical treatments | Medicare billing
- Advanced Certificate of Skin Cancer Medicine | Enrol now
Advanced dermoscopy | Curettage & Cautery | Diathermy | Lower leg grafts | Large ellipses
- Professional Certificate of Skin Cancer Surgery | Enrol now
Rotation flaps | Advancement flaps | Full thickness grafts | Dog ear repairs | Anaesthetic blocks
- Professional Diploma of Skin Cancer Surgery | SOLD OUT
Bilobed flaps | Reconstruction of lower eyelids, lip & ear defects | Anatomy | Perforator island flaps
Further dates and locations
In this skin cancer update, Associate Professor Giuseppe Argenziano discusses the findings of a study from May 2017 about the accuracy of pathologists’ diagnoses of melanoma.
The study found that the accuracy and reproducibility of the pathologists’ results were very low – in some cases, accuracy was just 25 percent.
In recent years, cancer treatment research has focused on immunotherapy – specifically, how to mobilise the immune system to attack cancer cells. The difficulty is identifying how cancer cells manage to disarm the T-cell fighters of the immune system in the first place, and then developing drugs to restore those damaged T-cells.
Patients with incurable cancers such as advanced melanoma have shown long-term responses to checkpoint inhibitor drugs, but they only work for around sixty percent of patients. This means cancer cells still have other ways of disabling the body’s immune system that are not remedied through the use of checkpoint inhibitors.
Skin Cancer Summit & Masterclasses
The 9th Skin Cancer Summit and Masterclasses saw international thought leaders in skin cancer medicine converge in Brisbane to collaborate with GPs from across Australia.
New findings suggest that pembrolizumab used in the neoadjuvant and adjuvant setting causes anti-tumour activity in patients with locally advanced squamous cell carcinoma of the head and neck. Continue reading “Pembrolizumab Promising in Treatment of Head and Neck Skin Cancer”
Data shows that adding afatinib to standard chemoradiation therapy does not improve disease-free survival among patients with squamous cell carcinoma of the head and neck.
Researchers from the Yale Cancer Centre have presented the findings of a randomised, double-blind, placebo-controlled, phase three trial of afatinib as adjuvant therapy after chemoradiation in primary unresected, high- or intermediate-risk, squamous cell cancer of the head and neck patients.